ICUI — ICU Medical, Inc.

ICU Medical, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $526 million, reflecting a 1% organic growth but a reported decline of 12% due to the deconsolidation of IV Solutions.
• Gross Margin: Increased to over 41%, benefiting from a favorable product mix.
• Adjusted EBITDA: $99 million, consistent with the previous year.
• Adjusted EPS: $1.97, up 15% from $1.72 year-over-year.
• Free Cash Flow: Strong at $28 million, with a full-year target of approximately $150 million.
• Debt and Cash: Ended the quarter with $1.3 billion in debt and $288 million in cash.

2. Strategic Updates and Business Highlights

• Business Segments:
  • Consumables: Grew 5% reported and 2% organic; expected to return to historical growth rates in Q2.
  • IV Systems: Achieved 8% reported and 6% organic growth, marking a record quarter for pumps.
  • Vital Care: Experienced a 14% organic decline and a 59% reported decline due to deconsolidation impacts.
• Product Development: Received multiple 510(k) clearances for new products, enhancing the oncology line and infection control offerings.
• Operational Improvements: Focused on reducing cash consumed in integration and remediation activities, with expected reductions in the second half of the year.

3. Forward Guidance and Outlook

• Growth Expectations: Anticipate continued organic growth in IV Systems and Consumables, with a balanced performance throughout the year rather than a back-half weighting.
• Margin Improvement: Targeting an additional 2 percentage points in gross margin improvements.
• Risks and Opportunities: While macroeconomic factors like oil prices pose risks, lower tariff expenses are expected to partially offset these costs.

4. Bad News, Challenges, or Points of Concern

• Deconsolidation Impact: The joint venture with Otsuka has led to significant revenue declines in the Vital Care segment.
• Market Volatility: Ongoing macroeconomic uncertainties, including fluctuating oil prices and tariff implications, could impact financial performance.
• Regulatory Delays: Additional testing requirements from the FDA for new hardware platforms may delay product launches, affecting growth timelines.

5. Notable Q&A Insights

• Infusion Systems Growth: The strongest growth driver was identified as Large Volume Parenterals (LVP), although specific growth figures were not disclosed.
• Installation Capacity: Improved synchronization of installation resources is expected to facilitate more balanced growth throughout the year.
• Vital Care Revenue Decline: The exit from a Japanese product line contributed to the revenue decline, but the overall impact was minor across other segments.
• Competitive Landscape: ICU Medical remains focused on maintaining pricing power and market share, with ongoing competitive opportunities in the infusion pump market.

Overall, ICU Medical reported stable financial performance amidst challenges from deconsolidation and macroeconomic factors, while maintaining a positive outlook on growth and operational improvements.